Researcher Profile Form First National Pediatric Brain Tumor Research Meeting March 9, 2025 - Jerusalem
Researcher: Dr. Revital Mandil-Levin
Basic Info
Title/Position: Founder, CEO and chairman Nanocarry Therapeutics Ltd.
Institution: Nanocarry Therapeutics Ltd.
Email: revital@nanocarry.com
Phone: 054-3161576
Current Role & Affiliation
Dr. Revital Mandil Levin is the CEO of NannoCarry
Research Focus
Nanocarry is developing a new class of brain therapeutics, which combines biological approaches with nanoparticles to allow biologics to cross the Blood Brain Barrier, creating first-in-class therapeutics for neuro-oncology indications and CNS diseases.
Current Projects Related to Pediatric Brain Tumors
Evaluation of NanoCarry’s technology in brain tumors is currently under evaluation.
Laboratory/Research Resources
NanoCarry’s technology may be included in a collaborative study evaluating it’s use with an innovative anti tumoral therapy
Collaboration Interests
combination of Biond’s technology with an anti tumoral therapy
Keywords
Drug delivery, Protein carrier, Targeted therapy,
Brief Bio
Dr. Mandil-Levin is currently the CEO and founder of Nanocarry Therapeutics Ltd., a private company developing a proprietary platform technology for the delivery of biologics across the blood-brain barrier for CNS indications.
Dr Mandil levin had served in multiple roles in innovative biotech companies including Anima Biotech, CollPlant Ltd. (NASDAQ: CLGN), a regenerative and aesthetic medicine company, NeuroDerm Ltd (NASDAQ: NDRM), a clinical-stage pharmaceutical company developing next-generation treatments for CNS disorders, and HealOr Ltd, a clinical-stage biopharmaceutical company that developed novel drugs for skin regeneration in hard to heal wounds and dermatological diseases. Prior to that she served as Business Development Manager at Proteologics Ltd.
Dr Mandil-Levin has a PhD in Biochemistry from Bar-Ilan University, Israel and an MBA from the Israeli College of Management School of Business.
